fashion -WSS

fashion

author：fashion 2025-09-03 03:36:16 - browse：7

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Abortion pill case raises question: who can sue the FDA?

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

There's no autism epidemic. It's an autism diagnosis epidemic

Will generative AI in health care meet the fate of IBM's Dr. Watson?

California store owner shot dead in dispute over displaying Pride flag: Police

Wegovy improves function in certain heart failure patients

Meadows told special counsel he could not recall Trump ever declassifying Mar

focus

fashion

explore

As demand for Covid shots wanes, Moderna seeks its next success

FDA advisory panel to debate high blood pressure devices

Medical leaders decry Supreme Court decision on affirmative action

Can U.S. cancer drug shortages be fixed?

Guidelines to prevent youth baseball injuries need more muscle

How to make over

DIEP, the 'gold standard' of breast reconstruction, is under threat

Vivek Ramaswamy made waves in the debate, much as in biotech

ChatGPT in medicine: STAT answers readers' burning questions

The Readout: Lenmeldy, GLP

leisure time

FDA advisory panel to debate high blood pressure devices

Readout Newsletter: Merck, Vertex, and Viking updates

The Readout: Lenmeldy, GLP

Roche subsidiary Foundation Medicine opens new headquarters

Readout LOUD podcast: mifepristone case, GLP

Decaf coffee targeted by food safety group under obscure FDA rule

leisure time

focus

hotspot

knowledge